Bio-Imaging Tech dips into the red in Q4

By Phil Taylor

- Last updated on GMT

Contract research organisation Bio-Imaging Technologies posted a 48 per cent hike on revenues in the fourth quarter of 2008, but still made a small net loss on the back of its CapMed division, which was sold last month.

The contribution of eClinical specialist Phoenix Data Systems, acquired by Bio-Imaging in March, was a major factor in the revenue increase.

For the full-year, revenues increased to $56.2m, up 50 per cent and with a $12.5m contribution from PDS, and despite the fourth-quarter net loss operating income accelerated 75 per cent to $8.5m in 2008.

Fourth-quarter service revenues came in at $15m, up from $10.1m a year earlier, and Bio-Imaging posted a net loss of $163,000.

Mark Weinstein, Bio-Imaging’s CEP, said that 2008 was “a record year​” for the company with a strong performance from its core business as well as the Phoenix Data acquisition. He said prospects for the company are good, as imaging and electronic data capture (EDC) are both seeing expanded use in clinical testing.

But like many of its peers Bio-Imaging is seeing a delay in projects as clients hold off on new investments during the economic downturn. He also said some major projects “being split into smaller components from a budget approval process.​”

In light of that Bio-Imaging has seen a near-9 per cent dip in backlog to around $93m at the end of 2008.

Bio-Imaging sold CapMed – a unit specialising in portable personal health record and health management technologies – in order to focus on its core clinical services business. The divestment has been reclassified as a discontinued business, so counts as a $2.4m operating loss for Bio-Imaging over the course of 2008.

Looking ahead to 2009, Bio-Imaging is predicting that revenues will advance to $60m-$63m.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars